Drug intelligence / Profile preview

Fertizyme

Development stage: Preclinical
Lead developer: Maia Fertility
Modality: Recombinant Proteins and Enzymes
Administration: Topical

Overview

Fertizyme is a preclinical-stage recombinant enzyme-based protein developed by Maia Fertility. It is designed for topical administration to address infertility and embryo implantation failure. The drug is being developed for both human applications, specifically in the context of in vitro fertilization (IVF), and veterinary use in species such as cattle, horses, camels, and endangered species. Its mechanism involves enzymatic action to enhance the success rate of embryo implantation by modulating the reproductive environment.

Brand names: Fertizyme
Other names: Fertizyme

Beyond the preview

Go deeper on Fertizyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fertizyme.

Explore the full profile